Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment

Ferring Pharmaceuticals150 enrolled

Overview

For both induction of remission and in maintenance of remission, different doses and treatment durations are used in practice. The aim of this study is to assess how mesalazine is used in clinical practice, at which doses and for how long and how these differences impact the patient disease state and work productivity.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Ulcerative Colitis

Interventions

mesalazineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with mild to moderate active ulcerative colitis with disease extension beyond the rectum (≥ 10 cm) who will receive oral Pentasa treatment (Compact sachets and/or tablets) for the treatment of the current active episode or in whom on oral Pentasa maintenance treatment induction of remission treatment will be initiated by dose escalation. Treatment combined with Pentasa enema (1g/100ml) is allowed. * Informed consent Exclusion Criteria: * Patients receiving treatment with one or more of the following: locally acting steroids (e.g. budesonide, beclomethasone), systemic steroids, immunosuppressants (e.g. thiopurines), biologicals (e.g. anti-Tumor Necrosis Factor-alpha)

Locations (1)

Gelre Ziekenhuizen (there may be other sites in this country)

Zutphen, Netherlands

Outcomes

Primary Outcomes

Time to dose reduction

Time frame: From Day 1 up to one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.